Healthcare

The past few years have witnessed huge strides in healthcare innovation, especially with the rapid rise of medtech and biotech. This innovation comes into play at all levels: from diagnosis to therapy and how the health system itself is actually organised. Connected objects, robotics, nanotechnologies, artificial intelligence — the potential for innovation is enormous and the Carnot Institutes are investing in the research needed to build the healthcare systems of both the present and the future.

LENSFREE

"Lensless" imagining
Carnot CEA LETI  Institute — Carnot preparing the future

Thanks to its extra large field of vision and compactness, Carnot CEA LETI’s lensless imager enables healthcare professionals to perform analyses at the patient’s bedside rather than in a lab. The technology is also at least ten times cheaper than an optical microscope and is capable of analysing 10 000 biological objects at the same time. This innovation is protected by 25 different patents.

HEPCAR

Identification of biomarkers in hepatocarcinoma cell lines using AI
Carnot Enterprise partnership Carnot AP-HP Institute -Owkin

The aim of this project was to study the clinical features of liver cancer sufferers. The findings of this research partnership between AP-HP and Owkin were published in the Hepatology scientific journal: “Predicting survival after hepatocellular carcinoma resection using deep-learning on histological slides” 

 

LDH

Lymphoma Data Hub 
Carnot CALYM Institute — Carnot preparing the future

As well as often being fragmented, big health data is of varying quality, incompatible in format and governed by disparate rules. This makes it harder to use and stifles the potential of AI, leading to lost opportunities in terms of competitiveness and research partnerships. The Lymphoma Data Hub aims to provide solutions to the problems encountered in lymphoma R&D projects.

SONOCLOUD®

Ultrasounds that make vessels more permeable
Carnot Enterprise partnership Carnot Brain Institute- Carthera

SonoCloud® is a medical implant designed by Professor Alexandre Carpentier, a neurosurgeon at La Pitié-Salpêtrière Hospital in Paris. It is inserted into the lining of the skull and activated iteratively during chemotherapy sessions using a transdermal microneedle and then connected to an external programmable generator. Ultrasounds are emitted inside the brain — without any bony obstacles — to allow the blood–brain barrier to be opened temporarily.

NEURONAUTE®

Carnot Enterprise partnership Carnot Brain Institute - BioSerenity

BioSerenity’s mission is to provide doctors and patients with round-the-clock care. The care in question is based on the acquisition and analysis of electrophysiology tests such as EEGs (electroencephalograms), ECGs (electrocardiograms) and PSGs (polysomnography) performed using connected clothing that patients may wear at home over a long period of time. Data is uploaded to a secure hosting platform that doctors may access at any time.

COVIDISC

A quick and reliable Covid test
Carnot IPGG Microfluidique Institute — Carnot preparing the future

Imagine a portable Covid test costing just ten dollars that gives results in less than an hour, and with a sensitivity equivalent to that of a PCR test. But this technology, which is set to shake up the diagnostics industry, is no pipedream and it already exists here in France. Its effectiveness has recently been proven and it is now undergoing numerous checks with a view to launching production in the near future.

ABILYCARE

A solution for detecting risks of fragility
Carnot Enterprise partnership Carnot  Cognition Institute - Engie Ineo

This solution was developed by Carnot Cognition’s Centre Borelli (merger of Cognac-G and CMLA labs) in partnership with Engie Ineo, and it can be used to assess the robustness of individuals using questionnaires and tests of an individual’s balance, walking skills and strength. It assesses fragility as part of diagnostic support: algorithms “factualise” clinical data and help health professional assess an individual’s fragility.

MACRILEN TM

Molecule for growth hormone dosage
Carnot Enterprise partnership Carnot Chimie Balard Cirimat Institute -  AETERNA ZENTARIS


Growth hormone (GH) deficiency is attributable to a problem with the hypothalamic-pituitary axis, which may be characterised by damage to the hypothalamus or pituitary gland. Before now, there was no straightforward way to regulate the dose of the hormone produced by the pituitary gland, however, Aeterna Zentaris has come up with MacrilenTM, an orally ingestible solution.